GW&K Investment Management LLC Has $33.04 Million Stock Holdings in Tandem Diabetes Care, Inc. $TNDM

GW&K Investment Management LLC lowered its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 5.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,721,649 shares of the medical device company’s stock after selling 168,481 shares during the quarter. GW&K Investment Management LLC owned approximately 4.01% of Tandem Diabetes Care worth $33,041,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Amalgamated Bank grew its stake in Tandem Diabetes Care by 3.5% in the third quarter. Amalgamated Bank now owns 19,617 shares of the medical device company’s stock valued at $238,000 after purchasing an additional 657 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of Tandem Diabetes Care by 8.8% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,101 shares of the medical device company’s stock valued at $319,000 after buying an additional 1,384 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Tandem Diabetes Care by 10.1% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,299 shares of the medical device company’s stock valued at $285,000 after buying an additional 1,399 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Tandem Diabetes Care by 8.9% during the second quarter. PNC Financial Services Group Inc. now owns 20,954 shares of the medical device company’s stock worth $391,000 after buying an additional 1,719 shares during the last quarter. Finally, Diversified Trust Co raised its position in Tandem Diabetes Care by 12.2% during the third quarter. Diversified Trust Co now owns 18,339 shares of the medical device company’s stock worth $223,000 after acquiring an additional 1,991 shares in the last quarter.

Tandem Diabetes Care Stock Down 3.3%

Shares of TNDM opened at $22.63 on Friday. The firm has a market cap of $1.55 billion, a P/E ratio of -7.37 and a beta of 1.63. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $29.65. The firm’s 50-day simple moving average is $21.42 and its 200 day simple moving average is $17.85.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, February 19th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. Tandem Diabetes Care had a negative return on equity of 68.23% and a negative net margin of 20.17%.The company had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $277.14 million. During the same quarter in the previous year, the company posted $0.01 earnings per share. The business’s revenue was up 15.1% on a year-over-year basis. On average, analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TNDM. Bank of America raised shares of Tandem Diabetes Care from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $30.00 in a research report on Friday, February 20th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $25.00 target price (up from $18.00) on shares of Tandem Diabetes Care in a research note on Friday, January 9th. Morgan Stanley boosted their price target on Tandem Diabetes Care from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Monday. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up from $14.00) on shares of Tandem Diabetes Care in a research note on Friday, February 20th. Finally, Mizuho set a $22.00 target price on Tandem Diabetes Care and gave the stock a “neutral” rating in a research note on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Tandem Diabetes Care currently has an average rating of “Hold” and an average target price of $28.11.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.